Most Liquid Pharmaceuticals Companies

Cash And Equivalents
Cash And EquivalentsEfficiencyMarket RiskExp Return
1ELTX Elicio Therapeutics
11.02 M
 0.11 
 4.84 
 0.55 
2MRK Merck Company
12.69 B
(0.17)
 1.20 
(0.20)
3CBGI Cannabusiness Group
14.78 K
 0.00 
 0.00 
 0.00 
4BMY Bristol Myers Squibb
9.12 B
 0.14 
 2.00 
 0.29 
5JNJ Johnson Johnson
5.37 B
(0.13)
 0.78 
(0.10)
6AZN AstraZeneca PLC ADR
4.52 B
(0.24)
 1.52 
(0.36)
7GSK GlaxoSmithKline PLC ADR
3.72 B
(0.24)
 1.47 
(0.35)
8TEVA Teva Pharma Industries
2.22 B
(0.08)
 1.79 
(0.14)
9LLY Eli Lilly and
2.07 B
(0.14)
 1.91 
(0.27)
10RPRX Royalty Pharma Plc
1.47 B
(0.11)
 1.00 
(0.11)
11ARVN Arvinas
1.27 B
 0.04 
 3.49 
 0.13 
12CGC Canopy Growth Corp
1.23 B
(0.06)
 5.16 
(0.28)
13RVNC Revance
233.82 M
(0.10)
 6.80 
(0.70)
14AMLX Amylyx Pharmaceuticals
206.68 M
 0.29 
 5.73 
 1.66 
15SAVA Cassava Sciences
197.23 M
(0.12)
 12.09 
(1.43)
16ANRO Alto Neuroscience,
57.42 M
(0.08)
 10.04 
(0.83)
17SXTP 60 Degrees Pharmaceuticals,
2.25 M
(0.02)
 7.05 
(0.14)
18IDCN Indocan Resources
219.37
 0.00 
 0.00 
 0.00 
19TAK Takeda Pharmaceutical Co
533.53 B
(0.12)
 0.90 
(0.10)
20NVO Novo Nordisk AS
37.47 B
(0.20)
 1.80 
(0.37)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes. Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).